By Dr Heloisa Zaccaron Milioli

Preprints

Shehadeh-Tout F; Milioli HH; Roslan S; Jansson PJ; Dharmasivam M; Graham D; Anderson R; Wijesinghe T; Azad MG; Richardson DR; Kovacevic Z, An Innovative Non-Hormonal Strategy Targeting Redox Active Metals to Down-Regulate Estrogen-, Progesterone-, Androgen- and Prolactin-Receptors in Breast Cancer, http://dx.doi.org/10.1101/2023.02.02.526543

Heng B; Bilgin AA; Lovejoy DB; Tan VX; Milioli HH; Gluch L; Busamante S; Sabaretnam T; Moscato P; Lim CK; Guillemin GJ, Differential kynurenine pathway metabolism in highly-metastatic aggressive breast cancer subtypes: beyond IDO1-induced immunosuppression, http://dx.doi.org/10.21203/rs.3.rs-57673/v2

Heng B; Bilgin AA; Lovejoy DB; Tan VX; Milioli HH; Gluch L; Moscato P; Lim CK; Guillemin GJ, Differential kynurenine pathway metabolism in highly-metastatic aggressive breast cancer subtypes: beyond IDO1-induced immunosuppression, http://dx.doi.org/10.21203/rs.3.rs-57673/v1

Mckinnon J; Milioli H; Purcell C; Chaffer C; Wadie B; Alexandrov T; Mitchell T; Ellis S, Enhancing Metabolite Coverage in MALDI-MSI using Laser Post-Ionisation (MALDI-2)., http://dx.doi.org/10.26434/chemrxiv-2023-sptss

Achinger-Kawecka J; Stirzaker C; Portman N; Campbell E; Chia K-M; Du Q; Laven-Law G; Nair SS; Yong A; Wilkinson A; Clifton S; Milioli HH; Alexandrou S; Caldon CE; Song J; Khoury A; Meyer B; Gee JMW; Schmitt A; Wong ES; Hickey TE; Lim E; Clark SJ, Epigenetic therapy targets the 3D epigenome in endocrine-resistant breast cancer, http://dx.doi.org/10.1101/2021.06.21.449340

Alexandrou S; Lee CS; Fernandez KJ; Wiharja CE; Eshraghi L; Reeves J; Reed DA; Portman N; Phan Z; Milioli HH; Nikolic I; Cadell AL; Croucher DR; Simpson KJ; Lim E; Hickey TE; Millar EKA; Alves CL; Ditzel HJ; Caldon CE, JNK pathway suppression drives resistance to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer, http://dx.doi.org/10.1101/2025.01.08.631992

Caldon C; Alexandrou S; Lee C; Fernandez K; Wiharja C; Eshraghi L; Reeves J; Reed D; Portman N; Phan Z; Milioli H; Nikolic I; Cadell A; Croucher D; Simpson K; Lim E; Hickey T; Millar E; Alves C; Ditzel H, JNK pathway suppression drives resistance to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer, http://dx.doi.org/10.21203/rs.3.rs-5920749/v1

Portman N; Milioli HH; Alexandrou S; Coulson R; Yong A; Fernandez KJ; Chia KM; Segara D; Parker A; Haupt S; Haupt Y; Tilley WD; Swarbrick A; Caldon CE; Lim E, MDM2 Inhibition in Combination with Endocrine Therapy and CDK4/6 Inhibition for the Treatment of ER-Positive Breast Cancer, http://dx.doi.org/10.1101/2020.06.09.140921

San Juan BP; Hediyeh-Zadeh S; Rangel L; Milioli HH; Rodriguez V; Bunkum A; Kohane FV; Purcell CA; Bhuva DD; Kurumlian A; Castillo L; Lim E; Gill AJ; Ganju V; Dear R; O’Toole S; Vargas AC; Hickey TE; Goldstein LD; Lock JG; Davis MJ; Chaffer CL, Targeting phenotypic plasticity prevents metastasis and the development of chemotherapy-resistant disease, http://dx.doi.org/10.1101/2022.03.21.22269988

Tilley W; Hickey T; Selth L; Chia KM; Milioli H; Laven-Law G; Roden D; Jindal S; Hui M; Finlay-Schultz J; Ebrahimie E; Birrell S; Stelloo S; Iggo R; Alexandrou S; Caldon C; Abdel-Fatah T; Ellis I; Zwart W; Palmieri C; Sartorius C; Swarbrick A; Lim E; Carroll J, The Androgen Receptor is a Tumour Suppressor in Estrogen Receptor Positive Breast Cancer, http://dx.doi.org/10.21203/rs.3.rs-62718/v1

Back to profile page